Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David Michael George Halpin (Exeter Devon, United Kingdom), David Halpin, David B. Price, Marjan Kerkhof. Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Eur Respir J 2015; 46: Suppl. 59, 3940

Member's Comments

No comment yet.

Related content which might interest you: Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Characteristics of patients newly prescribed a long acting bronchodilator in the US Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014